How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vedolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Entyvio — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Entyvio (vedolizumab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrin Receptor Antagonist [EPC]. Area: Gastroenterology.

marketed Integrin Receptor Antagonist [EPC] Integrin alpha-4/beta-7 Gastroenterology Live · refreshed every 30 min

Target snapshot

Entyvio (vedolizumab) — Takeda. Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Entyvio TARGET	vedolizumab	Takeda	marketed	Integrin Receptor Antagonist [EPC]	Integrin alpha-4/beta-7
Tysabri	Tysabri	University of Chicago	marketed		Integrin alpha-4/beta-1, Integrin alpha-4/beta-7
Tysabri	NATALIZUMAB	Biogen Idec	marketed	Integrin Receptor Antagonist [EPC]	α4β1 and α4β7 integrins	2004-01-01
TYRUKO	NATALIZUMAB-SZTN	SANDOZ INC	marketed	Integrin Receptor Antagonist [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrin Receptor Antagonist [EPC] class)

Biogen Idec · 1 drug in this class
SANDOZ INC · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Entyvio — Competitive Intelligence Brief. https://druglandscape.com/ci/vedolizumab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing